Organovo Holdings, Inc. announced that the company has hired Paul Gallant as its General Manager of the in vitro tissue service and product business. Mr. Gallant has more than 20 years of management and R&D experience in the drug discovery industry, most recently serving as chief operating officer for DiscoveRx. At Organovo, Mr. Gallant will be responsible for driving the success of the toxicology contract research services business, in close partnership with the sales and marketing team under Michael Renard and the Research and Development team under Sharon Presnell.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.7621 USD | -0.41% |
|
-5.73% | -31.34% |
31/05 | Organovo Holdings, Inc. Reports Earnings Results for the Full Year Ended March 31, 2024 | CI |
15/04 | Organovo's fatty liver disease drug meets main goal in mid-stage study | RE |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-31.34% | 11M | |
+38.65% | 39.1B | |
-8.62% | 38.76B | |
+26.95% | 31.24B | |
+10.74% | 25.9B | |
-13.50% | 25.8B | |
+44.87% | 14.06B | |
+34.36% | 13.12B | |
-7.14% | 11.32B | |
-12.61% | 10.68B |
- Stock Market
- Equities
- ONVO Stock
- News Organovo Holdings, Inc.
- Organovo Holdings, Inc. Appoints Paul Gallant as General Manager of the in Vitro Tissue Service and Product Business